OCEA Key Statistics, Chart & Performance
The current stock price of OCEA is 0.0205 USD. In the past month the price decreased by -63.91%. In the past year, price decreased by -98.47%.
OCEA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B |
Related stock screener links
About OCEA
Company Profile
Ocean Biomedical, Inc. is a biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 7 full-time employees. The company went IPO on 2021-09-15. The firm is focused on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The firm helps to accelerates the development and commercialization of assets from research universities and medical centers. In oncology, it is engaged in developing a mono-specific and two bi-specific humanized monoclonal antibodies (mAb), product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer (NSCLC), and of glioblastoma multiforme (GBM). The company offers three product candidates based on the novel target discoveries: a malaria vaccine candidate targeting either or both of PfSEA-1, and parasite antigen PfGARP, which is referred to as its ODA-570 candidate; a humanized mAb malaria therapeutic candidate targeting PfGARP, which is referred to as ODA-611 candidate, and a small molecule malaria therapeutic candidate targeting PfGARP, which is referred to as ODA-579 candidate.
Company Info
OCEAN BIOMEDICAL INC
515 Madison Ave Suite 8078
New York City NEW YORK US
Employees: 9
Phone: 16469082658
OCEAN BIOMEDICAL INC / OCEA FAQ
What does OCEAN BIOMEDICAL INC do?
Ocean Biomedical, Inc. is a biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 7 full-time employees. The company went IPO on 2021-09-15. The firm is focused on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The firm helps to accelerates the development and commercialization of assets from research universities and medical centers. In oncology, it is engaged in developing a mono-specific and two bi-specific humanized monoclonal antibodies (mAb), product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer (NSCLC), and of glioblastoma multiforme (GBM). The company offers three product candidates based on the novel target discoveries: a malaria vaccine candidate targeting either or both of PfSEA-1, and parasite antigen PfGARP, which is referred to as its ODA-570 candidate; a humanized mAb malaria therapeutic candidate targeting PfGARP, which is referred to as ODA-611 candidate, and a small molecule malaria therapeutic candidate targeting PfGARP, which is referred to as ODA-579 candidate.
What is the stock price of OCEAN BIOMEDICAL INC today?
The current stock price of OCEA is 0.0205 USD. The price decreased by -46.75% in the last trading session.
Does OCEAN BIOMEDICAL INC pay dividends?
OCEA does not pay a dividend.
How is the ChartMill rating for OCEAN BIOMEDICAL INC?
OCEA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the ownership structure of OCEAN BIOMEDICAL INC (OCEA)?
You can find the ownership structure of OCEAN BIOMEDICAL INC (OCEA) on the Ownership tab.
Can you provide the short interest for OCEA stock?
The outstanding short interest for OCEAN BIOMEDICAL INC (OCEA) is 0.05% of its float.
OCEA Technical Analysis
OCEA Financial Highlights
Over the last trailing twelve months OCEA reported a non-GAAP Earnings per Share(EPS) of -0.34. The EPS increased by 90.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1051% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |